Montag & Associates’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,408
| Closed | -$52K | – | 995 |
|
|
2022
Q3 | $52K | Sell |
3,408
-50
| -1% | -$581 | ﹤0.01% | 531 |
|
|
2022
Q2 | $26K | Sell |
3,458
-2,850
| -45% | -$20.1K | ﹤0.01% | 621 |
|
|
2022
Q1 | $57K | Hold |
6,308
| – | – | ﹤0.01% | 541 |
|
|
2021
Q4 | $44K | Sell |
6,308
-1,400
| -18% | -$14.6K | ﹤0.01% | 587 |
|
|
2021
Q3 | $88K | Hold |
7,708
| – | – | ﹤0.01% | 491 |
|
|
2021
Q2 | $123K | Hold |
7,708
| – | – | 0.01% | 447 |
|
|
2021
Q1 | $138K | Hold |
7,708
| – | – | 0.01% | 438 |
|
|
2020
Q4 | $104K | Buy |
+7,708
| New | +$93.1K | 0.01% | 445 |
|
|
2020
Q2 | – | Sell |
-10,208
| Closed | -$138K | – | 302 |
|
|
2020
Q1 | $138K | Sell |
10,208
-8,653
| -46% | -$164K | 0.01% | 275 |
|
|
2019
Q4 | $456K | Sell |
18,861
-2,065
| -10% | -$42.8K | 0.04% | 235 |
|
|
2019
Q3 | $402K | Sell |
20,926
-150
| -0.7% | -$3.44K | 0.04% | 235 |
|
|
2019
Q2 | $623K | Sell |
21,076
-225
| -1% | -$8.67K | 0.06% | 211 |
|
|
2019
Q1 | $1.01M | Sell |
21,301
-7,672
| -26% | -$338K | 0.09% | 168 |
|
|
2018
Q4 | $1.05M | Sell |
28,973
-9,367
| -24% | -$439K | 0.11% | 144 |
|
|
2018
Q3 | $2.36M | Buy |
+38,340
| New | +$2.46M | 0.21% | 112 |
|
Montag & Associates's AERI Position: Q4 2022 in Review
Montag & Associates sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 3,408 shares — an estimated $52K sold.
Montag & Associates first reported a position in AERI in Q3 2018 and held it in 15 quarters. The position peaked at $2.36M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Montag & Associates reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Montag & Associates sold 3,408 Aerie Pharmaceuticals shares in Q4 2022, an estimated $52K.
- Montag & Associates first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 15 quarters.
- Montag & Associates's Aerie Pharmaceuticals position peaked at $2.36M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.